Keywords: Gilead Sciences, Elvitagravir, Antivrals, HIV, Phase III
Gilead’s investigational antiviral elvitegravir meets 48-week primary goal
Article | 24 March 2011
USA-based Gilead Sciences (Nasdaq: GILD) says that a Phase III clinical trial of its investigational antiretroviral agent elvitegravir, a novel ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
